{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:22Z","timestamp":1753891222305,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To construct and validate a nomogram prediction model based on clinical characteristics and intestinal flora distribution in patients with chronic hepatitis B.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with chronic hepatitis B were divided into training set (<jats:italic>n<\/jats:italic>\u202f=\u202f175) and verification set (<jats:italic>n<\/jats:italic>\u202f=\u202f75) according to the ratio of 7:3 by complete random method. In the training set, multivariate logistic regression was used to analyze the risk factors for the failure of antiviral therapy and the nomogram prediction model was constructed. The ROC curve and calibration curve were drawn to evaluate the prediction efficiency of the nomogram model and were verified in the verification set.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no significant difference in the incidence, clinical characteristics and distribution parameters of intestinal flora between the training set and the verification set (<jats:italic>p<\/jats:italic>\u202f&amp;gt;\u202f0.05). Univariate analysis showed that the training set treatment ineffective group and the effective group had statistical differences in ALT, AST, hepatitis B virus DNA quantification, Shannon-Wiener index, Simpson index, Chao1 index, ACE index, relative abundance of <jats:italic>Sclerotinia sclerotiorum<\/jats:italic>, relative abundance of Bacteroides immitis, and PCA clustering separation (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05). Multivariate logistic regression analysis identified AST, hepatitis B virus DNA quantification, Shannon-Wiener index, Simpson index, and the relative abundance of Firmicutes and Bacteroides as independent risk factors for antiviral therapy failure (<jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.05). Further, the nomogram prediction model was constructed, and the nomogram model had good calibration and fitting between prediction and reality in the training set and the verification set (ROC curves were shown in the training set and the verification set); AUC of the nomogram model for predicting the antiviral treatment effect was 0.869 and 0.829.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The nomogram model shows good discriminative ability for predicting suboptimal antiviral response, requiring multicenter validation. It should complement, not replace, clinical judgment and virological monitoring, aiding early risk identification and targeted interventions.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1542104","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:21:31Z","timestamp":1749705691000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction and validation of a nomogram prediction model for antiviral efficacy based on clinical characteristics and intestinal microflora distribution in patients with chronic hepatitis B"],"prefix":"10.3389","volume":"12","author":[{"given":"Hongjie","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingqiang","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianbao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changyun","family":"Si","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1136\/gutjnl-2023-330691","article-title":"Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people","volume":"72","author":"Liu","year":"2023","journal-title":"Gut"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3350\/cmh.2023.0412","article-title":"Comprehensive approach to controlling chronic hepatitis B in China","volume":"30","author":"Shan","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2155018","DOI":"10.1080\/19490976.2022.2155018","article-title":"Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response","volume":"15","author":"Shen","year":"2023","journal-title":"Gut Microbes"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.cgh.2022.03.016","article-title":"Predicting the onset of hepatitis B virus-related acute-on-chronic liver failure","volume":"21","author":"Luo","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.3390\/ijms23073917","article-title":"Hepatitis B virus-associated hepatocellular carcinoma and chronic stress","volume":"23","author":"Noverati","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.3390\/v14020434","article-title":"Current trend in antiviral therapy for chronic hepatitis B","volume":"14","author":"Chien","year":"2022","journal-title":"Viruses"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1097\/HEP.0000000000000459","article-title":"Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase","volume":"78","author":"Huang","year":"2023","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.gastrohep.2022.05.014","article-title":"Antiviral therapy in hepatitis B virus-infected with immune-tolerant: a meta-analysis","volume":"46","author":"Huang","year":"2023","journal-title":"Gastroenterol Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.3748\/wjg.v28.i28.3555","article-title":"Gut microbiota alteration and modulation in hepatitis B virus-related fibrosis and complications: molecular mechanisms and therapeutic inventions","volume":"28","author":"Li","year":"2022","journal-title":"World J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","article-title":"Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review","volume":"19","author":"Di Vincenzo","year":"2024","journal-title":"Intern Emerg Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1129190","DOI":"10.3389\/fimmu.2023.1129190","article-title":"Alterations in gut immunological barrier in SARS-CoV-2 infection and their prognostic potential","volume":"14","author":"Eleftheriotis","year":"2023","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1152987","DOI":"10.3389\/fcimb.2023.1152987","article-title":"Gut microbiota dysbiosis with hepatitis B virus liver disease and association with immune response","volume":"13","author":"Yan","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.3390\/biom13081208","article-title":"Chronic hepatitis B infection: new approaches towards cure","volume":"13","author":"Ogunnaike","year":"2023","journal-title":"Biomol Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"944547","DOI":"10.3389\/fmed.2022.944547","article-title":"Development and validation of a non-invasive model to predict liver histological lesions in chronic hepatitis B patients with persistently norm al alanine aminotransferase and detectable viremia","volume":"9","author":"Hu","year":"2022","journal-title":"Front Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3350\/cmh.2022.0434","article-title":"Hepatitis B core-related antigen: a novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy","volume":"29","author":"Inoue","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/nu16050600","article-title":"In vitro lactic acid bacteria anti-hepatitis B virus (HBV) effect and modulation of the intestinal microbiota in fecal cultures from HBV-associated hepatocellular carcinoma patients","volume":"16","author":"Yang","year":"2024","journal-title":"Nutrients"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s00284-022-02877-7","article-title":"Association of gut microbiota with inflammatory bowel disease and COVID-19 severity: a possible outcome of the altered immune response","volume":"79","author":"Kaushal","year":"2022","journal-title":"Curr Microbiol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/nu16010009","article-title":"Berberine mediates the production of butyrate to ameliorate cerebral ischemia via the gut microbiota in mice","volume":"16","author":"Duan","year":"2023","journal-title":"Nutrients"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1826181","DOI":"10.1155\/2022\/1826181","article-title":"Characteristics and clinical significance of intestinal microbiota in patients with chronic hepatitis B cirrhosis and type 2 diabetes mellitus","volume":"2022","author":"Sun","year":"2022","journal-title":"J Diabetes Res"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1542104\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T05:21:32Z","timestamp":1749705692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1542104\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":20,"alternative-id":["10.3389\/fmed.2025.1542104"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1542104","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2025,6,12]]},"article-number":"1542104"}}